Trials / Recruiting
RecruitingNCT04571086
FAPI-PET for Tumor Detection
68-Ga-FAPI-PET for Tumor Detection: A Prospective Observational Trial
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- University Hospital, Essen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is a prospective observational trial investigating correlation with histopathology, positive predictive value, detection rate, reproducibility and impact on clinical management of 68-Ga-FAPI PET/CT or PET/MRI in patients receiving this imaging modality for tumor staging or restaging as part of clinical care.
Detailed description
68-Ga-fibroblast-activation-protein-inhibitors (68-Ga-FAPI) are novel Positron emission tomography (PET) tracers that were recently introduced for the imaging of patients with various cancer diseases. The fibroblast-activation-protein (FAP) is highly expressed in carcinoma-associated fibroblasts (CAFs) in the stroma of various tumor entities. The aim of this registry study is to collect data on FAPI expression, positive predictive value, detection rate, reproducibility and impact on clinical management of 68-Ga-FAPI PET/CT or PET/MRI on patients receiving this imaging modality at initial diagnosis or restaging as part of clinical care.
Conditions
Timeline
- Start date
- 2020-04-30
- Primary completion
- 2026-04-30
- Completion
- 2027-04-30
- First posted
- 2020-09-30
- Last updated
- 2023-11-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04571086. Inclusion in this directory is not an endorsement.